Chris Andrews (singer) then a string of hits for Sandie Shaw. They included "Girl Don't Come" (No. 3, 1964/65), "I'll Stop at Nothing" (No. 4, 1965), "Message Understood" (No. 6, 1965) and "Long Live Love" (No. 1, 1965). The latter remained a chart topper in the UK Singles Chart for three weeks. "Girl Don't Come" was covered by Cher on her debut album, "All I Really Want to Do". Also in 1965, Andrews as a solo artist, got to No. 3 in the same listings with "Yesterday Man", which peaked in Germany at No. 1 for four weeks; followed up with a No.
YM Biosciences YM Biosciences YM BioSciences Inc. was a Canadian drug development company primarily focused on advancing CYT-387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. YM BioSciences also had several preclinical programs underway with candidates from its library of compounds identified through internal research conducted at YM BioSciences Australia. The company also advanced other clinical-stage products, including Nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting agent (VDA). The company was listed on